FOXA1 is an independent prognostic marker for ER-positive breast cancer

FOXA1 is an independent prognostic marker for ER-positive breast cancer

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : Rutika J. Mehta Rohit K. Jain Samuel Leung Jennifer Choo Torsten Nielsen David Huntsman Harikrishna Nakshatri Sunil Badve
  • چاپ و سال / کشور: 2011

Description

Forkhead box protein A1 (FOXA1) is a ‘‘pioneer factor’’ that plays a role in controlling nearly 50% of estrogen receptor target genes. FOXA1 expression correlates with estrogen receptor (ER)-positivity especially in luminal subtype A breast cancers. The aim of this study was to investigate the precise role of FOXA1 in breast cancer using a large population-based cohort. Nuclear expression of FOXA1 was analyzed in a tissue microarray of 4,444 invasive breast cancer cases using immunohistochemistry and correlated with clinicopathologic variables using previously described methods and cutoff points. The entire cohort was equally divided into a training and validation set. All survival analyses were performed using a previously defined cutoff (3) for validation. Additional X-tile analysis performed to analyze prognostic effects of low and high FOXA1 levels identified 24 as a cutoff. Bonferroni–Holmes test was used as appropriate. FOXA1 expression significantly correlated positively with markers of good prognosis or ER-positivity, and negatively with tumor size, tumor grade, nodal status, Ki67, HER2 expression, and basal subtype (each P value \0.0001). In both survival analyses, FOXA1 was a significant predictor of breast cancer-specific survival (P\0.0001) and relapse-free survival (P\0.0001). FOXA1 was also an independent predictor of breast cancer- specific survival at 10 years using both cutoffs. Among the ER-positive subgroup treated with tamoxifen, FOXA1 was an independent prognostic marker using the 24 cutoff (P = 0.030). FOXA1 is a significant marker of good prognosis in breast cancer; it also identifies a subset of ER-positive tamoxifen treated patients at low risk of recurrence.
Breast Cancer Res Treat DOI 10.1007/s10549-011-1482-6 Received: 7 October 2010 / Accepted: 22 March 2011
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری